These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 1613645)

  • 1. A new approach to encapsulating non-steroidal anti-inflammatory drugs. V. Biopharmaceutical study of microcapsules of azapropazone coated with pectin and rutin.
    Meshali MM; el-Dien EZ; Omar SA; Luzzi LA
    J Microencapsul; 1992; 9(1):67-72. PubMed ID: 1613645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new approach to encapsulating nonsteroidal anti-inflammatory drugs. I. Bioavailability and gastric ulcerogenic activity.
    Meshali MM; el-Dien EZ; Omar SA; Luzzi LA
    J Microencapsul; 1987; 4(2):133-40. PubMed ID: 3504501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of particle size and film thickness on bioavailability and ulcerogenicity of encapsulated flufenamic acid.
    Foda A el-M ; el Said Y
    J Microencapsul; 1989; 6(2):227-32. PubMed ID: 2723967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicological studies on azapropazone.
    Adrian RW; Walker FS; Noel PR
    Curr Med Res Opin; 1976; 4(1):17-34. PubMed ID: 1261299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aceclofenac delivery by microencapsulation using LBL self-assembly for delayed release.
    Dharmendra K; Manisha P; Kymonil KM; Awasthi SS
    Pak J Pharm Sci; 2011 Oct; 24(4):495-502. PubMed ID: 21959811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new approach to encapsulating nonsteroidal anti-inflammatory drugs. IV. Effect of cellulose derivatives with different functional groups on the bioavailability and gastric ulcerogenic activity of acidic as well as basic nonsteroidal anti-inflammatory drugs.
    Meshali MM; el-Dien EZ; Omar SA; Luzzi LA
    J Microencapsul; 1989; 6(3):355-60. PubMed ID: 2569511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of drying technique on some physical properties of cross-linked high amylose/pectin mixtures.
    Soares GA; Carbinatto FM; Cury BS; Evangelista RC
    Drug Dev Ind Pharm; 2013 Feb; 39(2):284-9. PubMed ID: 22519692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azapropazone--twice or four times daily?
    Templeton JS
    Eur J Rheumatol Inflamm; 1981; 4(3):401-7. PubMed ID: 6242963
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of an oral rutin nanocrystal formulation.
    Mauludin R; Müller RH; Keck CM
    Int J Pharm; 2009 Mar; 370(1-2):202-9. PubMed ID: 19114097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of azapropazone following single oral and intravenous doses.
    Breuing KH; Gilfrich HJ; Meinertz T; Jähnchen E
    Arzneimittelforschung; 1979; 29(6):971-2. PubMed ID: 582795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption improvement of tranilast by forming highly soluble nano-size composite structures associated with α-glucosyl rutin via spray drying.
    Sato H; Fujimori M; Suzuki H; Kadota K; Shirakawa Y; Onoue S; Tozuka Y
    Eur J Pharm Biopharm; 2015 May; 92():49-55. PubMed ID: 25725261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of encapsulation of mefenamic acid with cationic Eudragit E on its bioavailability and gastric ulcerogenic activity in rabbits.
    Ramadan EM; el-Helw A; el-Said Y
    J Microencapsul; 1987; 4(2):125-32. PubMed ID: 3504500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection from gastrointestinal side-effects by azapropazone by its incorporation into a glucose-sodium acid citrate formulation.
    Rainsford KD; Dieppe PA; Pritchard MH; Rhodes J; Leach H; Russell RI; Walker FS; Upadhyay R; Hort JF
    Aliment Pharmacol Ther; 1991 Aug; 5(4):419-33. PubMed ID: 1777551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
    Verma MM; Kumar MT; Balasubramaniam J; Pandit JK
    Boll Chim Farm; 2003 Apr; 142(3):119-24. PubMed ID: 12806831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: in vitro characteristics and in vivo evaluation.
    Rabišková M; Bautzová T; Gajdziok J; Dvořáčková K; Lamprecht A; Pellequer Y; Spilková J
    Int J Pharm; 2012 Jan; 422(1-2):151-9. PubMed ID: 22079717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability.
    Alhnan MA; Murdan S; Basit AW
    Int J Pharm; 2011 Sep; 416(1):55-60. PubMed ID: 21679756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation of microencapsulated rutin and evaluation of bioactivity and stability upon in vitro digestive and dialysis conditions.
    Mel MMRD; Gunathilake KDPP; Fernando CAN
    Int J Biol Macromol; 2020 Sep; 159():316-323. PubMed ID: 32417545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pectin, beta-cyclodextrin, chitosan and albumin based gastroprotective systems for piroxicam maleate: Synthesis, characterization and biological evaluation.
    Mishra M; Chawla V; Chawla P
    Int J Biol Macromol; 2019 Feb; 122():127-136. PubMed ID: 30340003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new approach to encapsulating nonsteroidal anti-inflammatory drugs. III. Coating acidic as well as basic nonsteroidal anti-inflammatory drugs with cellulose derivatives having different functional groups.
    Meshali MM; el-Dien EZ; Omar SA; Luzzi LA
    J Microencapsul; 1989; 6(3):339-53. PubMed ID: 2569510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative gastroprotective effect of post-treatment with low doses of rutin and cimetidine in rats.
    Olaleye MT; Akinmoladun AC
    Fundam Clin Pharmacol; 2013 Apr; 27(2):138-45. PubMed ID: 21812818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.